Table 1.
Basal characteristics of 102 patients with invasive ductal carcinoma of the breast.
Figure 1.
Representative examples of immunohistochemical stainings at the invasive front from breast carcinomas (×200 magnification).
(A) Membranous staining of CD3 indicating T-lymphocytes. (B) Membranous staining of CD20 indicating B-lymphocytes. (C) Cytoplasmic staining of CD68 indicating macrophages.
Figure 2.
Distribution of the total number of CD markers by mm2 at the invasive front, in 102 breast carcinomas.
CD3 (A), CD20 (B) and CD68 (C).
Table 2.
Relationship between inflammatory cells count or ratio and clinico- pathological characteristics in 102 patients with invasive ductal carcinoma of the breast.
Figure 3.
Representative example of immunostaining.
MMP11 (A) and TIMP2 (B) immunostaining at the tumor center and MMP9 (C) and MMP14 (D) at the invasive front (×200 magnification), indicating the different cell types. Tumor cells (★), lymphocytes (<$>\raster(70%)="rg2"<$>) and macrophages (<$>\raster(70%)="rg1"<$>).
Table 3.
Relationship between inflammatory cells count or ratio at invasive front and MMPs/TIMPs expression by mononuclear inflammatory cells at invasive front or tumor center.
Figure 4.
Probability of relapse-free survival as a function of CD markers count for 102 patients with invasive ductal carcinoma.
CD3 count (A), CD20 count (B), CD68 count (C) and CD68/(CD3+CD20) ratio (D).
Table 4.
Cox's univariate (HR) and multivariate (RR) analysis of the significant relationships between MMPs, TIMPs expression or CD68/(CD3+CD20) ratio at the tumor center or at the invasive front, and relapse-free survival.